Abstract
The developments and research in the field of psychedelic drugs for curing mental illness, are discussed. John Halpern, associate director of substance abuse at Harvard university, has received approval from the US Food and Drug Administration (FDA) to give late-stage cancer patients the psychedelic drug MDMA. Since 2001, psychiatrist Francisco Moreno of the University of Arizona in Tucson has been testing psilocybin as a treatment for obsessive-compulsive disorder. In Charlston, South Carolina, physician Michael Mithoefer is carrying out a MAPS-sponsored clinical trial of MDMA as a treatment for post-traumatic stress disorder, in which he has given MDMA-assisted psychotherapy to six treatment-resistant patients, all traumatized by violent crimes.
Original language | English |
---|---|
Pages (from-to) | 36-39 |
Number of pages | 4 |
Journal | New Scientist |
Volume | 185 |
Issue number | 2488 |
State | Published - 26 Feb 2005 |